Webinar: Detecting meaningful mutations from liquid biopsies by Anchored Multiplex PCR

Liquid biopsies have the potential to be a less invasive method than traditional biopsies to detect advanced solid tumor mutational status. Cell free DNA (cfDNA) can be profiled from liquid biopsy samples, although the abundance is generally low, ranging from less than 1ng to 30ng cfDNA per mL blood in healthy individuals. Furthermore, only a small fraction of cfDNA originates from tumor cells as circulating tumor DNA (ctDNA), except in more advanced disease states. This ctDNA is typically highly fragmented (100-300bp), and thus NGS-based methods to detect oncogenic driver mutations from liquid biopsies must be sensitive enough to detect low-frequency mutations (allele fractions less than 2%) from low inputs (10-100ng) of highly fragmented material.
 
Anchored Multiplex PCR (AMP™) is proprietary target enrichment chemistry for NGS that is uniquely suited for highly fragmented material such as FFPE-derived nucleic acids and liquid biopsy-derived ctDNA. In this webinar, Josh Stahl, Chief Scientific Officer and General Manager at ArcherDX, will describe AMP-based ctDNA library preparation method, highlighting the use and advantages of molecular barcoded adapters used to unambiguously remove PCR duplicates, correct for PCR or sequencer-derived sequence errors, and flag run-to-run contamination. Josh will further talk about how the Archer® Reveal ctDNA™ 28 kit combines robust variant detection and quantitative analysis with single-day library prep for powerful, accurate and fast mutation analysis from liquid biopsies.
 
Learning objective 1: Understand both the value of mutation analysis from ctDNA in liquid biopsies and the challenges of analyzing ctDNA by next-generation sequencing.
 
Learning objective 2: Learn how the Archer Reveal ctDNA 28 kit uses Anchored Multiplex PCR target enrichment chemistry to detect and characterize ctDNA.